Zincretin 50/Zincretin 100

Zincretin 50 Sitagliptin. Zincretin 100 Sitagliptin phosphate

Monotherapy in patients inadequately controlled by diet & exercise alone & for whom metformin is inappropriate due to contraindications or intolerance. Dual oral therapy in combination w/ metformin when diet & exercise + metformin alone do not provide adequate glycaemic control; in combination w/ a PPARγ agonist (eg, thiazolidinedione) when use of a PPARγ agonist is appropriate & when diet & exercise + PPARγ agonist alone do not provide adequate glycaemic control. Triple oral therapy in combination w/ sulphonylurea & metformin when diet & exercise + dual therapy do not provide adequate glycaemic control; in combination w/ a PPARγ agonist & metformin when use of a PPARγ agonist is appropriate & when diet & exercise + dual therapy w/ these products do not provide adequate glycaemic control. Add-on to insulin (w/ or w/o metformin) when diet & exercise + stable dose of insulin do not provide adequate glycaemic control.

100 mg once daily. Patient w/ moderate renal impairment (GFR ≥30-<45 mL/min) 50 mg once daily, Severe renal impairment (GFR ≥15-<30 mL/min) or w/ ESRD (GFR <15 mL/min) including those requiring haemodialysis or peritoneal dialysis 25 mg once daily.

May be taken with or without food.

Hypersensitivity.

Discontinue use if hypersensitivity reaction; bullous pemphigoid is suspected. Not to be used in patients w/ type 1 diabetes or for the treatment of diabetic ketoacidosis. Patients w/ history of pancreatitis. Hypoglycaemia. Renal impairment. Not to be used during pregnancy & lactation. Not recommended in childn & adolescents 10-17 yr.

Hypoglycaemia; headache.

Alteration in renal clearance w/ potent CYP3AA4 inhibitors (ie, ketoconazole, itraconazole, ritonavir, clarithromycin) in patients w/ severe renal impairment or ESRD. Risk of digoxin toxicity.

Antidiabetic Agents

A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

Rx